You are in: eMedicine Specialties > Emergency Medicine > GASTROINTESTINAL Perirectal AbscessArticle Last Updated: Aug 28, 2007AUTHOR AND EDITOR INFORMATIONAuthor: Drew E Fenton, MD, Family Practice Physician, Ocean Medical Family and Urgent Care Drew E Fenton is a member of the following medical societies: American Academy of Emergency Medicine Editors: Michael S Beeson, MD, MBA, FACEP, Professor of Emergency Medicine, Northeastern Ohio Universities College of Medicine; Program Director, Emergency Medicine Residency, Summa Health System; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Eugene Hardin, MD, FACEP, FAAEM, Chair and Associate Professor, Department of Emergency Medicine, Charles R Drew University of Medicine and Science; Chair, Department of Emergency Medicine, Martin Luther King, Jr/Drew Medical Center; John Halamka, MD, Chief Information Officer, CareGroup Healthcare System, Assistant Professor of Medicine, Department of Emergency Medicine, Beth Israel Deaconess Medical Center; Assistant Professor of Medicine, Harvard Medical School; Jonathan Adler, MD, Attending Physician, Department of Emergency Medicine, Massachusetts General Hospital; Division of Emergency Medicine, Harvard Medical School Author and Editor Disclosure Synonyms and related keywords: perirectal abscess, perianal abscess, infection of the mucus-secreting anal glands, anorectal abscess INTRODUCTIONBackgroundPerirectal and perianal abscesses are commonly encountered ED problems. Timely and appropriate treatment is needed to prevent serious morbidity and mortality. This article focuses on perirectal abscess and provides some discussion of perianal abscess. These entities are distinct, with potentially different ED evaluation and different treatment and disposition. Differentiation of the more complex perirectal abscess from the simple perianal abscess is crucial. PathophysiologyPerirectal abscess arises from infection of the mucus-secreting anal glands, which drain into the anal crypts. Blockage of the duct is believed to be the initiating cause of infection. The abscess can then progress to involve the potential spaces filled with fatty areolar tissue, which have little resistance to infection. These spaces include the perianal, intersphincteric, ischiorectal, deep postanal space (connecting the ischiorectal space on each side posteriorly), and supralevator spaces. These spaces may become infected alone or in combination with one another. Perirectal abscess is usually an aerobic and anaerobic polymicrobial infection. Bacteroides fragilis is the predominant anaerobe. Other common bacteria include Escherichia coli and those of the genera Proteus, Bacteroides, and Streptococcus. Sources of bacteria are skin, bowel, and, rarely, the vagina.1 A variety of disease states is associated with the development of an abscess; these include Crohn disease, carcinoma, radiation fibrosis, trauma, Hodgkin disease, and immunocompromised states. Associated infectious causes include Chlamydia, Actinomyces, Gonococcus, Streptococcus, Bacteroides, and Proteus species; Staphylococcus aureus and Escherichia coli; and herpes, tuberculosis, and lymphogranuloma venereum. In contradistinction to perirectal abscess, perianal abscess is easily palpable and is not accompanied by fever, leukocytosis, and sepsis in the immunocompetent patient. Mortality/MorbidityIn rare instances, inappropriately treated perirectal abscess may result in death.
RaceNo racial predilection has been found. SexMen are affected more frequently than women, with a male-to-female predominance of 2:1 to 3:1. AgePerirectal abscess occurs in all age groups, from infants to elderly persons. The peak incidence is in the third and fourth decades of life. CLINICALHistoryThe history is critical in leading the physician to consider the diagnosis.
PhysicalThe physical examination findings may be normal, but a history that raises suspicion of a perirectal abscess should lead the physician to continue to pursue the diagnosis.
CausesThe cause of perirectal abscess is believed to be blockage of the perianal gland duct with resultant infection, rupture, and abscess formation. Risk factors are as follows:
DIFFERENTIALSAbdominal Pain in Elderly Persons Anal Fistulas and Fissures Hemorrhoids Inflammatory Bowel Disease Necrotizing Fasciitis Proctitis Rectal Prolapse
|
| Drug Name | Ampicillin and sulbactam (Unasyn) |
|---|---|
| Description | Drug combination of beta-lactamase inhibitor with ampicillin. Interferes with bacterial cell wall synthesis during active replication, causing bactericidal activity against susceptible organisms. Alternative to amoxicillin when unable to take medication PO. Covers skin, enteric flora, and anaerobes. Not ideal for nosocomial pathogens. |
| Adult Dose | 1.5 (1 g ampicillin + 0.5 g sulbactam) to 3 g (2 g ampicillin + 1 g sulbactam) IV/IM q6-8h; not to exceed 4 g/d sulbactam or 8 g/d ampicillin |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | Probenecid and disulfiram elevate ampicillin levels; allopurinol decreases ampicillin effects and has additive effects on ampicillin rash; may decrease effects of PO contraceptives |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Adjust dose in renal failure; evaluate rash and differentiate from hypersensitivity reaction |
| Drug Name | Imipenem cilastatin (Primaxin) |
|---|---|
| Description | Should be used for more severely ill ICU patients empirically. Pus and/or blood culture and sensitivity results, once available, should guide antibiotic selection. Predisposing and comorbid diseases may also guide empiric antibiotic selection. |
| Adult Dose | Base initial dose on severity of infection, and administer in equally divided doses; dose may range from 250-500 mg q6h IV for a maximum of 3-4 g/d Alternatively, 500-750 mg IM q12h or intra-abdominally |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | Coadministration with cyclosporine may increase CNS side effects of both agents; coadministration with ganciclovir may result in generalized seizures |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Adjust dose in renal insufficiency (adult adjustments) CrCl (mL/min) 80-50: 0.5 g q6-8h CrCl 50-10: 0.5 g q8-12h Hemodialysis (HD): 0.25-0.5 g after HD, then q12h Adjust dose in renal insufficiency; avoid use in children <12 y |
| Drug Name | Ampicillin (Marcillin, Omnipen, Polycillin) |
|---|---|
| Description | Broad-spectrum penicillin. Interferes with bacterial cell wall synthesis during active replication, causing bactericidal activity against susceptible organisms. Alternative to amoxicillin when unable to take medication PO. Those with prosthetic heart valves at risk for endocarditis should receive IV prophylactic antibiotics prior to any procedure. Ampicillin IV should be used, unless the patient is penicillin allergic, in which case cefazolin or clindamycin are appropriate choices. |
| Adult Dose | 250-500 mg PO q6h 500 mg to 1.5 g IM q4-6h 500 mg to 3 g IV q4-6h; not to exceed 12 g/d |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | Probenecid and disulfiram elevate ampicillin levels; allopurinol decreases ampicillin effects and has additive effects on ampicillin rash; may decrease effects of PO contraceptives |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Adjust dose in renal failure; evaluate rash and differentiate from hypersensitivity reaction |
| Drug Name | Cefazolin (Ancef, Kefzol, Zolicef) |
|---|---|
| Description | First-generation semisynthetic cephalosporin that by binding to 1 or more penicillin-binding proteins arrests bacterial cell wall synthesis and inhibits bacterial replication. Poor capacity to cross blood-brain barrier. Primarily active against skin flora, including S aureus. Typically used alone for skin and skin-structure coverage. Regimens for IV and IM dosing are similar. Primarily active against skin flora, including S aureus. Use in penicillin-allergic patients with prosthetic heart valves at risk for endocarditis. |
| Adult Dose | 250 mg to 2 g IV/IM q6-12h depending on severity of infection; not to exceed 12 g/d |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | Probenecid prolongs effect of cefazolin; coadministration with aminoglycosides may increase renal toxicity; may yield false-positive urine-dip test results for glucose |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Adjust dose in severe renal insufficiency (high doses may cause CNS toxicity); superinfections and promotion of nonsusceptible organisms may occur with prolonged use or repeated therapy |
| Drug Name | Clindamycin (Cleocin) |
|---|---|
| Description | Semisynthetic antibiotic produced by 7(S)-chloro-substitution of 7(R)-hydroxyl group of parent compound lincomycin. Inhibits bacterial growth, possibly by blocking dissociation of peptidyl tRNA from ribosomes, causing RNA-dependent protein synthesis to arrest. Widely distributes in the body without penetration of CNS. Protein bound and excreted by the liver and kidneys. Use in penicillin-allergic patients with prosthetic heart valves at risk for endocarditis. |
| Adult Dose | 150-450 mg/dose PO q6-8h; not to exceed 1.8 g/d 600-1200 mg/d IV/IM divided q6-8h depending on degree of infection |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; regional enteritis; ulcerative colitis; hepatic impairment; antibiotic-associated colitis |
| Interactions | Increases duration of neuromuscular blockade induced by tubocurarine and pancuronium; erythromycin may antagonize effects; antidiarrheals may delay absorption |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Adjust dose in severe hepatic dysfunction; no adjustment necessary in renal insufficiency; associated with severe and possibly fatal colitis by allowing overgrowth of Clostridium difficile |
These agents may help to blunt the pain of a diagnostic needle aspiration but is only partially effective.
| Drug Name | Lidocaine 1% (Xylocaine) |
|---|---|
| Description | Decreases permeability to sodium ions in neuronal membranes. This results in the inhibition of depolarization, blocking the transmission of nerve impulses. Ethylene chloride may be used in conjunction with lidocaine to blunt the pain of a diagnostic needle aspiration but is only partially effective. It should be sprayed over the area to be aspirated immediately prior to aspiration. |
| Adult Dose | 5-10 mL as a field block at the area of intended aspiration |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; avoid use in Adams-Stokes syndrome and Wolff-Parkinson-White syndrome |
| Interactions | None reported |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | For external or mucous membrane use only; do not use in eyes |
Pain control is essential to quality patient care. Analgesics ensure patient comfort, promote pulmonary toilet, and have sedating properties, which are beneficial for patients who experience pain. These agents are used for comfort and sedation and to blunt discomfort of diagnostic needle aspiration.
| Drug Name | Meperidine (Demerol) |
|---|---|
| Description | Analgesic with multiple actions similar to those of morphine; may produce less constipation, smooth muscle spasm, and depression of cough reflex than similar analgesic doses of morphine. May use in combination with promethazine to provide synergistic effect. |
| Adult Dose | 50-100 mg IV/IM with 25 mg promethazine IV/IM |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; MAOIs; upper airway obstruction or significant respiratory depression; during labor when delivery of premature infant is anticipated |
| Interactions | Monitor for increased respiratory and CNS depression with coadministration of cimetidine; hydantoins may decrease effects of meperidine; avoid with protease inhibitors |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus |
| Precautions | Caution in patients with head injuries because may increase respiratory depression and CSF pressure (use only if absolutely necessary); caution postoperatively and with history of pulmonary disease (suppresses cough reflex); increased dosing levels, because of tolerance, may aggravate or cause seizures (even without prior history); adjust dose in renal insufficiency (do not use in severe renal dysfunction); normeperidine metabolite accumulation may induce CNS toxicity; monitor closely for morphine-induced seizure activity if prior seizure history |
These agents are used to treat emesis.
| Drug Name | Promethazine (Phenergan) |
|---|---|
| Description | Antidopaminergic agent effective in treating emesis. Blocks postsynaptic mesolimbic dopaminergic receptors in brain and reduces stimuli to brainstem reticular system. May use in combination with meperidine to provide synergistic effect. |
| Adult Dose | 25 mg IV/IM with 50-100 mg meperidine IM/IV |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; children <2 y (incidences of death due to respiratory depression) |
| Interactions | May have additive effects when used concurrently with other CNS depressants or anticonvulsants; coadministration with epinephrine may cause hypotension |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Caution in cardiovascular disease, impaired liver function, seizures, sleep apnea, and asthma |
By binding to specific receptor sites these agents appear to potentiate the effects of γ-aminobutyric acid (GABA) and to facilitate inhibitory GABA neurotransmission and other inhibitory transmitters. Benzodiazepines are anxiolytics that may help patients apprehensive about needle aspiration, imaging studies, or surgery. Conscious sedatives may be considered by the emergency physician with equipment and experience necessary to manage the patient's airway if spontaneous ventilation become compromised.
| Drug Name | Midazolam (Versed) |
|---|---|
| Description | Shorter-acting benzodiazepine sedative-hypnotic useful in patients who require acute and/or short-term sedation. Midazolam is also useful for its amnestic effects. |
| Adult Dose | 1 mg IV slowly q2-3min up to 10 mg with the endpoint being slurred speech as an indicator of the desired hypnotic effect |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; preexisting hypotension; narrow-angle glaucoma |
| Interactions | Sedative effects of midazolam may be antagonized by theophyllines; narcotics and erythromycin may accentuate sedative effects of midazolam due to decreased clearance |
| Pregnancy | D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus |
| Precautions | Caution in congestive heart failure, pulmonary disease, renal impairment, and hepatic failure |
| Drug Name | Lorazepam (Ativan) |
|---|---|
| Description | Sedative hypnotic with short onset of effects and relatively long half-life. By increasing the action of GABA, which is a major inhibitory neurotransmitter in the brain, may depress all levels of CNS, including limbic and reticular formation. When patient needs to be sedated for longer than 24-h period, this medication is excellent. |
| Adult Dose | 0.5-2 mg IV q6h prn anxiety |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; preexisting CNS depression; hypotension; narrow-angle glaucoma |
| Interactions | Toxicity of benzodiazepines in CNS increases when used concurrently with alcohol, phenothiazines, barbiturates, and MAOIs |
| Pregnancy | D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus |
| Precautions | Caution in renal or hepatic impairment, myasthenia gravis, organic brain syndrome, or Parkinson disease |
Article Last Updated: Aug 28, 2007